Heart failure & cardiomyopathies
Role of Serum Cytokines in the Prediction of Heart Failure in Patients with Coronary Artery Disease
Authors' conclusion
The combination of VEGFR2, FLRG, IL-23, and FGF-21 can be used as a candidate biomarker for the prediction and prevention of HF in patients with CAD.
Study context
- Population
- Patients with coronary artery disease (CAD), with or without heart failure (HF), and healthy controlstraining dataset
- Participants
- 12 / 12 / 12
- Comparison
- Complicated with HF (CAD-HF) vs CAD-non HF vs healthy controls
- CAD-non HFn = 12
- CAD-HFn = 12
- Healthy controlsn = 12reference
- Outcome
- Cytokine biomarkers for predicting HF in CAD (SVM diagnostic model AUC)
Methodological detailsbiomarker discovery with external validation datasets, Human Cytokine Antibody Array; LASSO, recursive feature elimination and random forest feature selection; Support vector machine (SVM) model with ROC analysis; validation in GSE20681 and GSE59867 and by ELISA
- Biomarker discovery with external validation datasets
- Human Cytokine Antibody Array; LASSO, recursive feature elimination and random forest feature selection; SVM model with ROC analysis; validation in GSE20681 and GSE59867 and by ELISA
Performance
As reported in the abstract
SVM model (VEGFR2, FLRG, IL-23, FGF-21) diagnostic performance
- Differentially expressed proteins overlapping in the three comparison groups
- 12
- Optimal characteristic proteins identified (VEGFR2, FLRG, IL-23, FGF-21)
- 4
- AUC, training dataset
- 0.944
- AUC, GSE20681 validation dataset
- 0.773
- AUC, GSE59867 validation dataset
- 0.745
Further findings
Expression trends of the 4 crucial proteins
- Training dataset trends consistent with validation dataset and ELISA
Original publication
Role of Serum Cytokines in the Prediction of Heart Failure in Patients with Coronary Artery Disease. ESC Heart Fail. Published 22 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →